223 related articles for article (PubMed ID: 38372871)
21. Prevention and treatment of postmenopausal osteoporosis.
Tella SH; Gallagher JC
J Steroid Biochem Mol Biol; 2014 Jul; 142():155-70. PubMed ID: 24176761
[TBL] [Abstract][Full Text] [Related]
22. New developments in the treatment of osteoporosis.
Eriksen EF; Halse J; Moen MH
Acta Obstet Gynecol Scand; 2013 Jun; 92(6):620-36. PubMed ID: 22646526
[TBL] [Abstract][Full Text] [Related]
23. Preventing osteoporosis in symptomatic postmenopausal women.
Gallagher JC; Levine JP
Menopause; 2011 Jan; 18(1):109-18. PubMed ID: 20661164
[TBL] [Abstract][Full Text] [Related]
24. Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis.
Wu J; Zhang Q; Yan G; Jin X
J Orthop Surg Res; 2018 Aug; 13(1):194. PubMed ID: 30071889
[TBL] [Abstract][Full Text] [Related]
25. Prescription drug therapies for prevention and treatment of postmenopausal osteoporosis.
O'Connell MB
J Manag Care Pharm; 2006 Jul; 12(6 Suppl A):S10-9; quiz S26-8. PubMed ID: 17269853
[TBL] [Abstract][Full Text] [Related]
26. Drug utilization analysis of osteoporosis medications in seven European electronic health databases.
Tan EH; Robinson DE; Jödicke AM; Mosseveld M; Bødkergaard K; Reyes C; Moayyeri A; Voss A; Marconi E; Lapi F; Reinold J; Verhamme KMC; Pedersen L; Braitmaier M; de Wilde M; Ruiz MF; Aragón M; Bosco-Levy P; Lassalle R; Prieto-Alhambra D; Sanchez-Santos MT
Osteoporos Int; 2023 Oct; 34(10):1771-1781. PubMed ID: 37436441
[TBL] [Abstract][Full Text] [Related]
27. Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.
Palacios S; Agodoa I; Bonnick S; Van den Bergh JP; Ferreira I; Ho PR; Brown JP
J Clin Endocrinol Metab; 2015 Mar; 100(3):E487-92. PubMed ID: 25514106
[TBL] [Abstract][Full Text] [Related]
28. The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis.
Nicolopoulos K; Moshi MR; Stringer D; Ma N; Jenal M; Vreugdenburg T
Arch Osteoporos; 2023 Jan; 18(1):18. PubMed ID: 36624318
[TBL] [Abstract][Full Text] [Related]
29. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
Josse R; Khan A; Ngui D; Shapiro M
Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
[TBL] [Abstract][Full Text] [Related]
30. Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF).
Cooper C; Reginster JY; Cortet B; Diaz-Curiel M; Lorenc RS; Kanis JA; Rizzoli R
Curr Med Res Opin; 2012 Mar; 28(3):475-91. PubMed ID: 22356102
[TBL] [Abstract][Full Text] [Related]
31. Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis.
Beaudoin C; Jean S; Bessette L; Ste-Marie LG; Moore L; Brown JP
Osteoporos Int; 2016 Sep; 27(9):2835-2844. PubMed ID: 27120345
[TBL] [Abstract][Full Text] [Related]
32. New management options for osteoporosis with emphasis on SERMs.
McClung MR
Climacteric; 2015; 18 Suppl 2():56-61. PubMed ID: 26503459
[TBL] [Abstract][Full Text] [Related]
33. Bisphosphonates and other bone agents for breast cancer.
O'Carrigan B; Wong MH; Willson ML; Stockler MR; Pavlakis N; Goodwin A
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD003474. PubMed ID: 29082518
[TBL] [Abstract][Full Text] [Related]
34. A review of combination regimens for osteoporosis--prevention and treatment.
Miller E; Kalin MF
Int J Fertil Womens Med; 2002; 47(5):198-204. PubMed ID: 12469706
[TBL] [Abstract][Full Text] [Related]
35. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
36. Update of current therapeutic options for the treatment of postmenopausal osteoporosis.
Epstein S
Clin Ther; 2006 Feb; 28(2):151-73. PubMed ID: 16678639
[TBL] [Abstract][Full Text] [Related]
37. The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women.
Komm BS; Morgenstern D; A Yamamoto L; Jenkins SN
Expert Rev Clin Pharmacol; 2015; 8(6):769-84. PubMed ID: 26482902
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline.
Eastell R; Rosen CJ; Black DM; Cheung AM; Murad MH; Shoback D
J Clin Endocrinol Metab; 2019 May; 104(5):1595-1622. PubMed ID: 30907953
[TBL] [Abstract][Full Text] [Related]
39. Selective estrogen receptor modulators (SERMs): new alternatives for osteoarthritis?
Lugo L; Villalvilla A; Largo R; Herrero-Beaumont G; Roman-Blas JA
Maturitas; 2014 Apr; 77(4):380-4. PubMed ID: 24602552
[TBL] [Abstract][Full Text] [Related]
40. Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis.
Miyoshi A; Kameda H; Nagai S; Nakamura A; Miya A; Takase T; Atsumi T; Miyoshi H
J Diabetes Investig; 2021 Jul; 12(7):1293-1300. PubMed ID: 33141482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]